Russell Lewis
Russell E. Lewis, Pharm.D.

Assistant Professor
University of Houston College of Pharmacy
Houston, TX
Pharm.D., University of Kansas

Post-Doctoral Training
Residency – Barnes Jewish Hospital at
                Washington University Medical Center. St Louis, MO
Fellowship – Infectious Diseases Research,
                University of Iowa, Iowa City, IA

Research Interests
Invasive fungal infections in cancer patients
Antibacterial/Antifungal pharmacodynamics
Infectious Diseases Clinical Rotation (M.D. Anderson Cancer Center)
American Society for Microbiology
International Society for Anti-Infective Pharmacology
American College of Clinical Pharmacy
American Association of Colleges of Pharmacy
Society of Infectious Diseases Pharmacists
American Society for Health-System Pharmacists
Honors & Awards
New Investigator Research Award, SIDP 1998.
Facts and Comparisons Excellence in Clinical Communications, 1996.
Recent Publications
Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrobial Agents & Chemotherapy. 1998;42:1207-1212.

Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans using a dynamic in vitro mycotic infection model. Antimicrobial Agents & Chemotherapy. 1998;42:1382-1386.

Lewis RE, Klepser ME, Pfaller MA. Update on clinical antifungal susceptibility testing for Candida species. Pharmacotherapy. 1998;18:509-515

Klepser ME, Lewis RE, Pfaller MA. Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options. Annals of Pharmacotherapy. 1998;32:1353-1361.

Lewis RE, Klepser ME. Update on clindamycin: New pharmacokinetic and pharmacodynamic data. Infections in Medicine. 1998;15:726-731.

Lewis RE, Klepser ME, Pfaller MA. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. Journal of Infectious Disease Pharmacotherapy. 1999;3:61-83.

Lewis RE, Klepser ME. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. American Journal of Health-System Pharmacists. 1999;56:525-534.

Lewis RE, De Lallo VC, Klepser ME. Antifungal pharmacodynamics. Research Signposts. In Press

Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrobial Agents Chemotherapy. 1999;42:2005-2009.

Lewis RE, Klepser ME, Pfaller MA. In vitro pharmacodynamics of 5-fluorocytoisine (5-FC) determined by time-kill methods. Diagnostic Microbiology and Infectious Diseases. In Press.